Sutent 12.5 mg hard capsules
Sponsors
AstraZeneca AB, Bristol Myers Squibb International Corporation, F. Hoffmann-La Roche AG, Bristol-Myers Squibb Services Unlimited Company, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Conditions
Advanced MalignanciesAdvanced or Metastatic Renal Cell CarcinomaAdvanced or metastatic renal cell carcinomaAdvanced soft tissue and bone sarcomasAdvanced solid tumorLocally advanced/metastatic renal cell carcinomaMET-drivenMultiple myeloma
Phase 1
Phase 2
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
RecruitingCTIS2023-506914-32-00
Start: 2020-05-05Target: 307Updated: 2026-01-19
Phase 3
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
CompletedCTIS2023-504761-23-00
Start: 2014-11-19End: 2025-01-14Target: 578Updated: 2024-12-09
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Active, not recruitingCTIS2023-509711-83-00
Start: 2017-10-27Target: 265Updated: 2025-07-16
A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
CompletedCTIS2024-512016-22-00
Start: 2017-12-27End: 2025-06-04Target: 5Updated: 2025-06-02
SAMETA A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA)
RecruitingCTIS2022-503105-38-00
Start: 2021-10-22Target: 62Updated: 2025-06-06
An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)
Active, not recruitingCTIS2023-506184-34-00
Start: 2019-08-09Target: 104Updated: 2025-11-10